FindTrial
Sign In

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease - Comparing several biomarkers to predict liver fibrosis in patients with nonalcoholic fatty liver disease

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000023286
Enrollment
300
Registered
2016-07-23
Start date
2016-06-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nonalcoholic fatty liver disease

Interventions

None listed

Sponsors

Nippon Medical School Chiba Hokusoh Hospital
Lead Sponsor
National Center for Global Health and Medicine (NCGM) Shinmatsudo Central General Hospital
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1,Taking alcohol less than 20g/day for female and 30g/day for male respectively 2,patients diagnosed as NAFLD by liver biopsy

Exclusion criteria

Exclusion criteria: 1,alcohol abuse (quantity of ethanol intake more than 20g/day for female and 30g/day for male respectively) 2,type 1 diabetes, 3,positive HBs antigen, HCV antibody, or HIV antibody, 4,other liver diseases, such as autoimmune hepatitis, primary biliary cirrhosis, and drug-induced liver disorder 5,being treated with oral vitamin E preparation and thiazolidinediones for NAFLD or other disorders

Design outcomes

Primary

MeasureTime frame
The values of AUC, sensitivity, specificity, PPV, and NPV for various biomarkers. Correlation between serum fibrotic markers for predicting liver fibrosis.—

Countries

Japan

Contacts

Public ContactMasanori Atsukawa

Nippon Medical School Chiba Hokusoh Hospital Division of Gastroenterology

atsukawa-nms@umin.ac.jp0476-99-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026